Literature DB >> 12534282

Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells.

Daniel L Greenberg1, Gregory J Mize, Thomas K Takayama.   

Abstract

Thrombin and trypsin induce cell signaling through a subclass of G-protein-coupled receptors called the protease-activated receptors (PARs). In many cells, PAR signaling results in the activation of RhoA and other members of the Rho family of small GTPases which are involved in cytoskeletal reorganization. The expression of PARs and their role in the activation of Rho GTPases in prostate cancer cells are not clearly known. FACS analysis demonstrated that the androgen-dependent LNCaP cells express PAR1, PAR2, and PAR4 but not PAR3. Stimulation with thrombin and trypsin resulted in the rapid activation of RhoA in a dose-dependent manner with an EC(50) of 1.0 and 5 nM, respectively. Activation of RhoA was enhanced by, but not dependent on, the presence of 1 nM dihydrotestosterone. Inhibition of the proteolytic properties of thrombin by hirudin and trypsin by diisopropyl fluorophosphate abolished the observed RhoA activation. Stimulation with 150 microM PAR-activating peptides TFFLRN (PAR1), SLIGKV (PAR2), and AYPGKF (PAR4) demonstrated that PAR1 and PAR2 mediated protease-activated RhoA signaling. Fluorescent microscopy studies showed that LNCaP cells treated with either thrombin (10 nM) or trypsin (10 nM) developed an increased number of filopodia, stress fibers, and focal adhesions relative to untreated cells. These observations represent the first report of PAR signaling in prostate cancer cells as well as the ability of PAR2 to mediate RhoA activation. Since the activation of RhoA is important for cytoskeletal reorganization, we postulate that PAR-mediated RhoA activation may be a major signaling pathway in the biology of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12534282     DOI: 10.1021/bi027100x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

Review 1.  Proteinase-activated receptors in the lower urinary tract.

Authors:  James D Moffatt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-10       Impact factor: 3.000

2.  Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis.

Authors:  Xiaotun Zhang; Wenbin Wang; Lawrence D True; Robert L Vessella; Thomas K Takayama
Journal:  Prostate       Date:  2009-05-15       Impact factor: 4.104

3.  ALEX1, a novel tumor suppressor gene, inhibits gastric cancer metastasis via the PAR-1/Rho GTPase signaling pathway.

Authors:  Li Pang; Jian-Fang Li; Liping Su; Mingde Zang; Zhiyuan Fan; Beiqin Yu; Xiongyan Wu; Chen Li; Min Yan; Zheng-Gang Zhu; Bingya Liu
Journal:  J Gastroenterol       Date:  2017-03-17       Impact factor: 7.527

4.  ROCK1 feedback regulation of the upstream small GTPase RhoA.

Authors:  Alan T Tang; William B Campbell; Kasem Nithipatikom
Journal:  Cell Signal       Date:  2012-03-11       Impact factor: 4.315

Review 5.  Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer.

Authors:  Andrea Pia Elste; Iver Petersen
Journal:  J Mol Histol       Date:  2010-06-20       Impact factor: 2.611

6.  Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells.

Authors:  Kasem Nithipatikom; Ana Doris Gomez-Granados; Alan T Tang; Adam W Pfeiffer; Carol L Williams; William B Campbell
Journal:  Endocrinology       Date:  2011-11-15       Impact factor: 4.736

7.  RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.

Authors:  Lucy J Schmidt; Kelly Duncan; Neelu Yadav; Kevin M Regan; Alissa R Verone; Christine M Lohse; Elena A Pop; Kristopher Attwood; Gregory Wilding; James L Mohler; Thomas J Sebo; Donald J Tindall; Hannelore V Heemers
Journal:  Mol Endocrinol       Date:  2012-03-28

8.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

9.  Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.

Authors:  Eric Yang; Adrienne Boire; Anika Agarwal; Nga Nguyen; Katie O'Callaghan; Powen Tu; Athan Kuliopulos; Lidija Covic
Journal:  Cancer Res       Date:  2009-07-21       Impact factor: 12.701

Review 10.  Regulation of RhoGEF proteins by G12/13-coupled receptors.

Authors:  Sandra Siehler
Journal:  Br J Pharmacol       Date:  2009-02-18       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.